GI Toxicities are the most common drug-induced adverse events in human clinical trials. Unfortunately, they are poorly predicted by rodent models. View our poster presentation from the 2023 SOT meeting authored by James Levi. It describes how a new human-derived cell model provides an efficient and informative screen for drug effects on intestinal cell proliferation. In addition, it screens barrier function toxicities. This model closely resembles natural human physiology.
Poster: A Sensitive and Specific Human Primary Stem Cell-Based In Vitro Assay for Predicting The Gastrointestinal Toxicity Risk of Therapeutic Agents
Ready to design your study?
Well-to-Well Consistency: Seeding, Confluence, and Real Signal vs Noise
Posted by Ben Scruggs
Some of the most damaging variability in a gut assay never involves the drug at all. It lives between neighboring…
Reproducibility in Your Hands: Why an Assay Drifts When It Moves Between Labs
Posted by Ben Scruggs
A model can be perfectly reproducible in the lab that built it and still fall apart the moment it lands…
Biological vs Technical Replicates: Powering a Gut Assay You Can Trust
Posted by Ben Scruggs
Here is a mistake that survives peer review more often than it should. A team runs an experiment once, measures…


